default author photo

Albrecht Stenzinger

Heidelberg University - Institute of Pathology

Im Neuenheimer Feld 224

Heidelberg, 69120

Germany

German Cancer Consortium

Germany

  • Heidelberg University - Institute of Pathology

  • German Cancer Consortium

SCHOLARLY PAPERS

5

DOWNLOADS

365

TOTAL CITATIONS

0

Scholarly Papers (5)

Actions:
Email selected abstracts
1.

Leveraging Off-Target Reads in Panel Sequencing: A Comprehensive Technical Pilot Study

Number of pages: 16 Posted: 11 Sep 2023
Markus Ball, Iordanis Ourailidis, Klaus Kluck, Michael Menzel, Martina Kirchner, Michael Allgäuer, Kwang Yong Timothy Tay, Fabian Schnecko, Anna-Lena Volckmar, Hannah Goldschmid, Olaf Neumann, Stefan Fröhling, Peter Schirmacher, Jan Budczies, Albrecht Stenzinger and Daniel Kazdal
Heidelberg University, Vienna Biocenter - Research Institute of Molecular Pathology (IMP), Heidelberg University, Heidelberg University - University Hospital Heidelberg, Heidelberg University - University Hospital Heidelberg, Heidelberg University, National University of Singapore (NUS) - Singapore General Hospital, Heidelberg University - University Hospital Heidelberg, Heidelberg University, Heidelberg University - University Hospital Heidelberg, Heidelberg University, National Center for Tumor Diseases, Heidelberg University - Institute of Pathology, Heidelberg University, Heidelberg University - Institute of Pathology and Heidelberg University
Downloads 114 (640,165)

Abstract:

Loading...

2.

Analysis of Rare Fusions in Nsclc: Genomic Architecture and Clinical Implications

Number of pages: 25 Posted: 31 May 2023
Huriye Seker-Cin, Timothy Tay Kwang Yong, Daniel Kazdal, Klaus Kluck, Markus Ball, Olaf Neumann, Hauke Winter, Felix J. Herth, Claus-Peter Heußel, Rajkumar Savai, Peter Schirmacher, Michael Thomas, Jan Budczies, Michael Allgäuer, Petros Christopoulos, Albrecht Stenzinger and Anna-Lena Volckmar
Heidelberg University, Heidelberg University, Heidelberg University, Heidelberg University, Heidelberg University, Heidelberg University, Heidelberg University, Heidelberg University - Thoraxklinik, and Translational Lung Research Center Heidelberg (TLRCH), Heidelberg University, affiliation not provided to SSRN, Heidelberg University - Institute of Pathology, Heidelberg University, Heidelberg University, Heidelberg University, Heidelberg University, Heidelberg University - Institute of Pathology and Heidelberg University
Downloads 100 (720,278)

Abstract:

Loading...

receptor tyrosine kinase, targeted therapy, NGS, oncogenic fusion

3.

A retrospective, multicentre analysis within the national Network Genomic Medicine lung cancer in Germany to detect RET fusions as a possible mechanism of resistance in patients with EGFR mutations

Number of pages: 19 Posted: 03 Dec 2025
Cornelia Kropf-Sanchen, Nikolaj Frost, Jonas Kuon, Martin Wermke, Stefan Krueger, Florian Fuchs, Marcel Wiesweg, Petros Christopoulos, Michael Thomas, Nadine Teresa Gaisa, Maria Josten, Carina Wenzel, Juliane Buth, Franziska Glanemann, Albrecht Stenzinger, Matthias F. Froelich, Melanie Janning, Maike Collienne, Verena Haselmann and Sonja Loges
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Duisburg-Essen - University Hospital Essen, Heidelberg University, Heidelberg University, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Heidelberg University - Institute of Pathology, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and Heidelberg University - University Medical Centre Mannheim
Downloads 57 (1,010,164)

Abstract:

Loading...

non-small-cell lung cancer, targeted therapy, EGFR, RET, resistance mechanism, combined TKI-therapy, personalized medicine, digital droplet PCR

4.

Integrated Clinico-Molecular Characterization Identifies RAS Activation and CDKN2A Deletion As Independent Adverse Prognostic Factors in Cancer of Unknown Primary

Number of pages: 51 Posted: 28 Sep 2019
Tilmann Bochtler, Anna Reiling, Volker Endris, Thomas Hielscher, Anna-Lena Volckmar, Olaf Neumann, Martina Kirchner, Jan Budczies, Lukas C. Heukamp, Jonas Leichsenring, Michael Allgäuer, Daniel Kazdal, Harald Löffler, Wilko Weichert, Peter Schirmacher, Albrecht Stenzinger and Alwin Krämer
German Cancer Research Center (DKFZ) - Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) - Clinical Cooperation Unit Molecular Hematology/Oncology, Heidelberg University - Institute of Pathology, German Cancer Research Center (DKFZ) - Division of Biostatistics, Heidelberg University - Institute of Pathology, Heidelberg University - Institute of Pathology, Heidelberg University - Institute of Pathology, Heidelberg University - Institute of Pathology, Institute for Haematopathology Hamburg, Heidelberg University - Institute of Pathology, Heidelberg University - Institute of Pathology, Heidelberg University - Institute of Pathology, German Cancer Research Center (DKFZ) - Clinical Cooperation Unit Molecular Hematology/Oncology, Heidelberg University - Institute of Pathology, Heidelberg University - Institute of Pathology, Heidelberg University - Institute of Pathology and German Cancer Research Center (DKFZ) - Clinical Cooperation Unit Molecular Hematology/Oncology
Downloads 57 (1,000,027)

Abstract:

Loading...

Cancer of unknown primary (CUP), mutational profiling, KRAS, CDKN2A, prognosis, targeted therapy

5.

Ros1 Fusions in Resected Stage I-Iii Adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape Project

Number of pages: 38 Posted: 01 May 2024
Ernst-Jan M. Speel, Urania Dafni, Erik Thunissen, Jan Hendrik Rüschoff, Cathal O Brien, Jacek Kowalski, Keith M. Kerr, Lukas Bubendorf, Irene Sansano Valero, Leena Joseph, Mark Kriegsmann, Atilio Navarro, K. Monkhorst, Line Bille Madsen, Javier Hernandez Losa, Wojcicech Biernat, Albrecht Stenzinger, Andrea Rüland, Lisa M. Hillen, Nesa Marti, Miguel A. Molina-Vila, Tereza Dellaporta, Roswitha Kammler, solange peters, Rolf A. Stahel, Stephen P. Finn, Teodora Radonic and Consortium Lungscape
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University Hospital Zurich, affiliation not provided to SSRN, Medical University of Gdansk, Aberdeen Royal Infirmary, University of Basel - University Hospital Basel, affiliation not provided to SSRN, The University of Manchester - Manchester University NHS Foundation Trust, Heidelberg University - University Hospital Heidelberg, affiliation not provided to SSRN, Netherlands Cancer Institute Antoni van Leeuwenhoek, Aarhus University - Aarhus University Hospital, affiliation not provided to SSRN, Medical University of Gdansk, Heidelberg University - Institute of Pathology, affiliation not provided to SSRN, Maastricht University, affiliation not provided to SSRN, Quirón-Dexeus University Institute - Pangaea Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, Centre Hospitalier Universitaire Vaudois (CHUV), affiliation not provided to SSRN, affiliation not provided to SSRN, University of Amsterdam - University Medical Center and affiliation not provided to SSRN
Downloads 37 (1,236,159)

Abstract:

Loading...

ROS1, lung adenocarcinoma, NSCLC, Lungscape